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Objectives: to evaluate the role of Triclosan (Irgasan) in the prevention of prosthetic graft infection.
Material and methods: fifty-one pigs were assigned randomly to six groups. Group I (graft) and II (graft and Triclosan)
were control groups. Groups III (graft) and IV (grafts and Triclosan) were contaminated with 2×107 CFU/ml S. aureus.
Groups V (graft) and VI (graft and Triclosan) were intraoperatively contaminated with 2×107 CFU/ml S. aureus and
reoperated on after 7 days. Remaining animals were sacrificed on day 28. The end point of the investigation was vascular
graft infection, defined as the bacteriological and/or histological proof of infection.
Results: in both control groups no vascular graft infections were detected in Groups I and II. All of the group III animals
presented but none of the group IV developed a graft infection (p<0.02). All of the group V animals presented and 10 of
12 animals developed a graft infection.
Conclusion: in this animal model Triclosan bonding appears effective in preventing prosthetic graft infection. However,
the in situ replacement of Triclosan-protected grafts was not successful in the treatment of graft infection.
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Introduction to prosthetic Dacron material (Intergard prostheses)
for prevention of primary graft infection and in con-
Vascular prosthetic infection is associated with a high trolling infection after the in situ replacement of an
infected vascular prosthesis.rate of limb loss and mortality. Despite the use of
prophylactic systemic antibiotics, the incidence of graft
infection ranges between 0.5 and 2.5% in patients
Material and Methodsreceiving a vascular graft.1 The mechanism of graft
infection may be perioperative contamination, post-
Graft material and Triclosan bondingoperative wound infection or systemic bacteraemia.
Once a prosthetic graft is infected, the treatment almost
Collagen coated knitted Dacron prostheses (In-always requires its removal and replacement by au-
tergard, Intervascular, La Ciotat, France) were usedtologous vein or arteries.2 If autologous grafts are not
in this study. All grafts were 4 mm in diameter withavailable extra-anatomic reconstruction is required.
a length of 2 cm.The development of infection-resistant alloplastic vas-
Triclosan (Irgasan) is attracted to the graft by mo-cular prostheses may therefore be useful in the primary
lecular bonding. Further details of the manufacturingprevention of graft infection as well as in the treatment
process can not be published because of corporateof infected grafts by in situ reconstruction. Triclosan
secrecy reasons (Intervascular (La Ciotat, France)).(Irgasan) is a bactericidal and fungicidal substance
with broad spectrum antimicrobial characteristics.
It was the purpose of this experimental study to
Bacterial strain and graft contaminationevaluate the effect of topical application of Triclosan
∗ Please address all correspondence to: T. Hernandez-Richter, Chi-
Staphylococcus aureus ATCC 29213 was obtained fromrurgische Klinik, Klinikum Großhadern, Ludwig Maximilians-Uni-
versita¨t Mu¨nchen, Marchioninistr. 15, 81377 Mu¨nchen, Germany. the Department of Virology and Microbiology, Faculty
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of Medicine, Ludwig Maximilian University of Mu- untreated Dacron prosthesis was contaminated prior
to the closure of the incision. Reoperation on post-nich. The strain was susceptible to Triclosan (minimal
inhibitory concentration 10−12 mg/l). The con- operative day 7 including total graft excision, de-
bridement and replacement with a Triclosan-coatedcentration of the inoculating bacterial suspension used
was adjusted photometrically to a concentration of Dacron prosthesis. Animals of group V and VI under-
went reoperation with graft removal and in situ pros-2×107 CFU/ml.
After replacing part of the common femoral artery thetic replacement. The femoral graft was exposed
through the previous inguinal excision applying sterilewith a 2-cm segment of Dacron, 1 ml of the inoculating
suspension was directly applied to the surface of the surgical technique. After proximal and distal control
of the femoral vessel adjacent to the graft, local signsgraft.
of infection were reported, including tissue in-
flammation, perigraft fluid and cavity formation, ab-
sence of graft incorporation, and anastomotic
Pig model dehiscence with false aneurysm formation. The graft
was then totally excised, including anastomotic sites
Fifty-one German Landrace pigs weighing 20–30 kg and 3 mm of the femoral vessel proximal and distal
underwent replacement of the common femoral artery to the graft. The perivascular tissue was debrided. The
with a Dacron vascular prosthesis (Intergard) under graft was submitted to bacteriological and histological
sterile surgical technique. analysis. After graft excision a 2-cm piece of Dacron
All pigs received a perioperative antibiotic pro- graft was implanted in situ in end to end fashion with
phylaxis with amoxycillin/clavulanic acid (Aug- 6-0 polypropylene suture. The incision was closed in
mentin, Smith Kline Beecham, Mu¨nchen, Germany) standard surgical technique.
and 5000 IE Heparin-Natrium (Heparin-Natrium Anaesthesia and systemic antibiotic prophylaxis, as
25000, Ratiopharm, Essex Pharma, Mu¨nchen, Ger- well as prophylaxis perioperatively with heparin and
many). The common femoral artery was exposed and 500 mg aspirin, was carried out as for the primary
transected and a 2-cm graft (4 mm diameter) was intervention. At day 28 animals were anaesthetised
inserted in double end to end fashion with 6-0 poly- and euthanised to recover the grafts for bacteriological
propylene sutures (Prolene (Surgipro, Autosuture, and histological study. Information regarding graft
Elancourt, France)). In animals receiving local con- patency, the extent of graft incorporation and the
tamination, 2×107 CFU/ml Staphylococcus aureus presence of perigraft fluid or cavity was recorded.
ATCC 29213 was applied to the surface of the graft Specimens of liver, kidney, the graft as well as perigraft
prior to closure of the incision. tissue were also taken for bacteriological and histo-
Postoperatively, all animals were fed ad libitum. All logical examination. As preliminary analyses revealed
animals received 500 mg of Aspirin (Bayer, Lever- most grafts to be infected, group VI was enlarged by
kusen, Germany) on postoperative days 1 to 7 and four animals in order to further support the hypothesis
100 mg of aspirin from day 8 to day 28. Postoperative of the missing therapeutic effect of the Triclosan bon-
controls were carried out on days 1, 3, 7 and 28 ded graft. All animal care complied with the ‘‘Prin-
after primary operation and after reoperation. Clinical ciples of Laboratory Animal Care and the Guide for
controls consisted of digital bypass control, ultrasound Care and Use of Laboratory Animals’’ (Tierschutz-
Doppler examination or angiography in selected cases. genehmigung 211-2531-60/97).
Animals were randomly assigned to six groups.
Animals of group I (control) received a Dacron pros-
thesis. Control group II was treated by Triclosan coated
prosthesis. Prophylaxis group III received a Dacron Histopathologic studies
prosthesis and was contaminated prior to the closure
of the incision with 2×107 Staphylococcus aureus ATCC The samples were fixed in formaldehyde, cut and
stained with HE (Haematoxylin-Eosin) or EvG (Elastic29213. Prophylaxis group IV with a Triclosan-coated
Dacron prosthesis was also contaminated. Treatment van Gieson). All tissues are examined for signs of
inflammation and infection and classified semi-group V received an untreated Dacron graft and local
contamination. Seven days after the primary procedure quantitatively (grade I: single granulocytes, grade II:
several granulocytes, grade III: high number of gran-reoperation with graft excision, debridement of the
perigraft tissue, washing with 500 ml 0.9% saline so- ulocytes, infiltration of the graft by granulocytes and
bacteria). In addition, the liver was studied for toxiclution and implantation of a new untreated Dacron
prosthesis took place. Group VI (treatment) with an alterations.
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Bacteriological studies Contamination of unprotected graft with 2×107 CFU
Staphylococcus aureus induced graft infection in all
Following reoperation and euthanasia, swabs were animals of group III. Although graft patency was
taken from subcutaneous tissue and the grafts. Stand- maintained in six of eight animals, two had complete
ardised samples from the graft, perigraft tissue, blood anastomotic disruption and the graft was incorporated
and urine were collected and stored under sterile in none of the cases. Triclosan bonding grafts (group
conditions. Graft material and perigraft tissue was IV) completely protected the animals from graft in-
trypsinised. One hundred microlitres of the suspension fection. No histological or bacteriological signs of in-
were plated on blood agar. With a positive bacterial fection could be detected, all grafts were well
culture the species were identified. Staphylococci were incorporated, and there was no anastomotic dis-
characterised by combined latex and haema- ruption, and all grafts were patent on day 28. This
gglutination test for proof of clamping factor and reduction in graft infection in group IV compared to
protein A as well as other specific antigens (Slidex group III was significant (p=0.014). Graft con-
Staph-Kit, Bio Me´rieux, Marcy l’Etoile, France) also in tamination with 2×107 Staphylococcus aureus caused
order to differentiate between Staphylococcus aureus graft infection in all but one of the 19 animals of
and coagulase-negative staphylococci. In the case of groups V and VI. The uninfected animal was excluded
an uncertain reaction further biochemical investigation from further evaluation. The grafts as well as the
using the commercially available API ID32 Staph-Kit perigraft tissue were massively infiltrated by Staphy-
(Bio Me´rieux) was carried out. lococcus aureus. On histological examination massive
infiltration by granulocytes and abscess formation or
fistulas could be demonstrated in all specimens. Re-
operation of group V animals did not cure the animalsHPLC (High Pressure Liquid Chromatography)
from graft infection. All newly implanted grafts be-
came reinfected, none of them was patent, three pre-The graft, perigraft tissue, liver and kidney tissue,
sented with anastomotic disruption, all showedblood serum and urine were examined for the presence
massive perigraft infiltration, and in none of the casesof Triclosan employing HPLC measurement.
was the graft incorporated (Table 1). Surprisingly
enough, there was one of the six animals without proof
of Staphylococcus aureus at autopsy on day 28. On
End point analysis bacteriologic examination there were sterile conditions
in this one animal (Table 2). Histological examination,
The end point of the examination was graft infection, however, proved infection to be present in this animal
defined as microbiological and/or histopathological as well. In group VI in situ graft replacement with a
proof of infection. Triclosan protected graft only cured two of the 12
animals from graft infection. In seven of 12 animals
the graft was patent, anastomotic disruption was found
in three of 12 animals and half of the specimens
Statistical analysis repeated massive perigraft inflammation. Evaluation
on the basis of histological and bacteriological proof
The data from these experiments were analysed with of infection led to the final result that only two animals
the two-tailed Exact Fisher Test. Statistical significance were free from graft infection by the implantation of
was assigned when p-values were less than 0.05. the Triclosan replacement graft.
HPLC measurement detected Triclosan on all Tri-
closan-bonded prostheses in median concentrations of
0.006 (range 0.002–0.033 mg/g graft weight [groupResults
II: median 0.006 (range 0.002–0.01); group IV: 0.005
(0.003–0.007); group VI: 0.01 (0.002–0.033). DifferenceThree pigs died before their scheduled sacrifice: two
between groups not significant (Mann–Whitney)].during induction of anaesthesia and one during rou-
Traces of Triclosan were also found in perigraft tissuetine blood sampling on day one after operation. The
and in the liver. In serum, urine and kidney tissueanimals of both control groups (group I: unprotected
Triclosan was not detected. No signs of toxicity weregraft and group II: Triclosan graft) showed excellent
found on histological examination of liver and kidneygraft incorporation without histological or micro-
biological signs of infection. tissue.
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Table 1. Macroscopic and histological evaluation of vascular grafts in the standardised in vivo infection model.
Macroscopic and Graft Anastomosis Graft Wall adherent
histological evaluation patency disruption incorporation thrombus
Group I 7/7 0/7 7/7 5/7
Control, unprotected graft
Group II 6/7 0/7 7/7 5/7
Control, Triclosan graft
Group III 6/8 1/8 1/8 6/8
Contamination, unprotected graft
Group IV 7/7 0/7 7/7 4/7
Contamination, Triclosan graft
Group V∗ 0/6 3/6 0/6 2/6
Reoperation, unprotected graft
Group VI∗ 7/12 4/12 5/12 4/12
Reoperation, Triclosan graft
∗All primary grafts were infected.
Table 2. Bacteriological and histological evaluation of vascular grafts in the standardised in vivo infection model.
Bacteriological and Bacteriological Bacteria other S. aureus Histological graft Bacteriological and
histological evaluation graft infection than S. aureus infection histological graft
infection
Group I 0/7 0/7 0/7 0/7 0/7
Control, unprotected graft
Group II 0/7 0/7 0/7 0/7 0/7
Control, Triclosan graft
Group III 8/8 1/8 8/8 6/8 8/8
Contamination, unprotected graft
Group IV 0/7 0/7 0/7 0/7 0/7‡
Contamination, Triclosan graft
Group V∗ 5/6 4/6 2/6 6/6 6/6
Reoperation, unprotected graft
Group VI† 8/12 7/12 1/12 10/12 10/12
Reoperation, Triclosan graft
∗All primary grafts were infected with S. aureus.
†One primary graft was not infected.
‡Significant difference between group III and IV, p=0.01.
Discussion We choose the pig model previously described by
Muhl.6 It was not only the aim to examine the ef-
In 1996 Manouguian3 first reported that Triclosan could fectiveness of Triclosan in the prevention of primary
graft infection, but also to examine also the ability ofbe bound directly to a prosthetic vascular graft and
successfully treated two patients with femoropopliteal Triclosan to protect vascular grafts in the treatment of
established vascular graft infection.8graft infection. Rego¨s4 demonstrated that Triclosan
was highly effective against a wide variety of Gram- Following intraoperative local contamination with
2×107 CFU (colony forming units) Staphylococcuspositive and negative organisms and fungi. Triclosan
was employed in our department, but our results aureus Triclosan-protected grafts were highly effective.
While direct contamination of unprotected Intergardwere not as favourable as those of Manouguian.3 We
therefore decided to examine the binding char- prostheses caused vascular graft infection in all tested
animals (8/8), none of the Triclosan-bonded graftsacteristics of Triclosan to various graft materials, re-
examine the antimicrobial potential of the substance showed histological or bacteriological signs of infection
(0/8). The difference between the two groups wasand then perform an in vivo study using a standardised
infection model as proposed by Torsello.5 highly significant (p<0.2).9
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However, treating vascular graft infection with Tri- randomised studies. In the case of high grade infection
the in situ replacement using antimicrobial bondedclosan-protected replacement grafts was not as effect-
prosthesis can not be recommended.ive. Prior to the use of Triclosan a variety of antibiotics
has been examined. Rifampin showed the highest
affinity and binding for the longest duration of time
to synthetic grafts.10–14 The binding of rifampin to gel- References
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